Φορτώνει......
Randomized Phase II Designs
As the use of molecularly targeted agents, which are anticipated to increase overall and progression-free survival (OS and PFS), but not necessarily tumor response, has increased in oncology, there has been a corresponding increase in the recommendation and use of randomized phase II designs. Such d...
Αποθηκεύτηκε σε:
Κύριοι συγγραφείς: | , , , , |
---|---|
Μορφή: | Artigo |
Γλώσσα: | Inglês |
Έκδοση: |
2009
|
Θέματα: | |
Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3774021/ https://ncbi.nlm.nih.gov/pubmed/19276275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2031 |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|